C4 THERAPEUTICS, INC.

(CCCC)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
6.870 USD   +2.38%
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb

01/10/2022 | 02:25pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
C4 THERAPEUTICS, INC. 2.38% 6.87 Delayed Quote.-78.66%
ON SEMICONDUCTOR CORPORATION 6.07% 58.5 Delayed Quote.-13.87%
All news about C4 THERAPEUTICS, INC.
05/16C4 THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/16C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluat..
CI
05/16C4 Therapeutics Says First Patient Dosed in Early Trial of Cancer Drug
MT
05/16C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CF..
GL
05/09HC Wainwright Adjusts Price Target on C4 Therapeutics to $35 From $63, Reiterates Buy R..
MT
05/05C4 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
05/05C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
05/05C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highli..
GL
04/28Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Ris..
MT
04/18UBS Adjusts C4 Therapeutics Price Target to $26 From $64, Maintains Buy Rating
MT
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 35,0 M - -
Net income 2022 -141 M - -
Net cash 2022 221 M - -
P/E ratio 2022 -2,49x
Yield 2022 -
Capitalization 335 M 335 M -
EV / Sales 2022 3,25x
EV / Sales 2023 3,92x
Nbr of Employees 121
Free-Float 86,9%
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 6,87 $
Average target price 25,67 $
Spread / Average Target 274%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren A. White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.-78.66%335
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002